CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Webcasts Abstract Library Committee Members
 
HBV-Single Disease Content  
Featured Article

Webcasts
HBV/HDV-ACT Connect (ADVANCING CURATIVE TREATMENTS)   Educational Webcast
Hepatitis B and D Infection   Educational Webcast
HBV/HDV Hot Topics & Virtual Roundtable   Educational Webcast
HBV, HCV, and HDV   Educational Webcast
 
 
Slide Library
   Released: 2023
Webcast
Stopping All Therapy in HBV Clinical Trials: What Should Be the Criteria for Discontinuation
23 slides
 
 
   Released: 2023
Webcast
New Insights Into The Biology Of HDV: Implications For Drug Development
42 slides
 
 
   Released: 2023
Webcast
HBV Overview of the Last 3 Years For Drug Development: Phase 2 Trials
43 slides
 
 
   Released: 2023
Webcast
Emerging Therapies for HBV in the Next Three Years (Pre-clinical to Phase 1)
31 slides
 
 
   Released: 2023
Webcast
What Are the Most Promising Immunomodulatory Therapies for HBV Infection?
29 slides
 
 
   Released: 2023
Webcast
Emerging Concepts and Data CpAMS Third and Fourth Generation
33 slides
 
 
   Released: 2023
Webcast
Does the New Data on HBV DNA Integration and HBsAg Production Effect the Design and Definition of Treatment Endpoints of Phase II and Phase III Studies?
20 slides
 
 
   Released: 2023
Webcast
Is there a real difference between ETV and TDF/TAF in relapse and HCC?
27 slides
 
 
   Released: 2023
Webcast
How Do We Fit FNA and Liver Biopsy Into HBV Drug Development and Design? Should All Studies Have FNA Subset and Examine Intrahepatic Immune Activity? CccDNA? Integrants?
19 slides
 
 
   Released: 2023
Webcast
Should All Patients With HDV Be Treated?
22 slides
 
 
   Released: 2023
Webcast
HDV Update: Review of the Last 3 Years
18 slides
 
 
   Released: 2023
Webcast
Hepatitis Delta: How Should Bulevirtide Be Used in Clinical Practice
27 slides
 
 
   Released: 2023
Webcast
What Other Therapies Are Being Developed for HDV Infection? NAPS, Lambda, and Lonafarnib
36 slides
 
 
   Released: 2023
Webcast
What Is the Role of Interferon Therapy in HDV?
30 slides
 
 
   Released: 2021
Webcast
HBV Alliance: Expert Recommendations on Managing Patients with Chronic Hepatitis B
56 slides
 
 
   Released: 2021
Webcast
Acute HBV
17 slides
 
 
   Released: 2021
Webcast
Chemotherapy/Reactivation
26 slides
 
 
   Released: 2021
Webcast
Current Management of Chronic Hepatitis B
30 slides
 
 
   Released: 2021
Webcast
Epidemiology of HBV
34 slides
 
 
   Released: 2021
Webcast
Evaluation of the Patient With Chronic HBV
26 slides
 
 
   Released: 2021
Webcast
Everything Old Is New Again!
41 slides
 
 
   Released: 2021
Webcast
Extrahepatic Manifestations of Hepatitis B
34 slides
 
 
   Released: 2021
Webcast
HBsAg Quant HBV Genotyping HBV RNA Quant Where We Are in 2020
41 slides
 
 
   Released: 2021
Webcast
HBV & Hepatitis D (Delta)
26 slides
 
 
   Released: 2021
Webcast
HBV and Liver Cancer
34 slides
 
 
   Released: 2021
Webcast
HBV and NAFLD
35 slides
 
 
   Released: 2021
Webcast
HBV Coinfection With HCV or HIV
35 slides
 
 
   Released: 2021
Webcast
HBV: New Therapies & Clinical Trials
37 slides
 
 
   Released: 2021
Webcast
Hepatitis B Screening: CDC, AASLD, USPSTF
24 slides
 
 
   Released: 2021
Webcast
Hepatitis B: Treatment Endpoints
27 slides
 
 
   Released: 2021
Webcast
Hepatitis B: Update on Treatment Guidelines
27 slides
 
 
   Released: 2021
Webcast
How to Diagnose Hepatitis B
25 slides
 
 
   Released: 2021
Webcast
Immunization for HBV
31 slides
 
 
   Released: 2021
Webcast
Management of HBV: New Data
26 slides
 
 
   Released: 2021
Webcast
Natural History of HBV
39 slides
 
 
   Released: 2021
Webcast
Treatment of Hepatitis B: Controversies 2020
63 slides
 
 
   Released: 2021
Webcast
Update on Hepatitis B
54 slides
 
 
   Released: 2021
Webcast
WHO Hepatitis Elimination Targets
46 slides
 
 
   
     
 
 
 
Abstract Library
1.Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN trials
 

Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000878. Online ahead of print.

 

Muhammad Atif Zahoor 1, Joshua B Feld 1, Hsing-Hua Sylvia Lin 2, Alexander I Mosa 1, Loghman Salimzadeh 1, Robert P Perrillo 3, Raymond T Chung 4, Kathleen B Schwarz 5, Harry LA Janssen 1 6, Adam J Gehring 1 7, Jordan J Feld 1
 
2.A care coordination program to support patients with hepatitis B virus at Kaiser Permanente Mid-Atlantic States
 

BMC Health Serv Res. 2024 Apr 18;24(1):482. doi: 10.1186/s12913-024-10907-2.

 

M Cabell Jonas 1, Yi-Shin Sheu 2, Kara Wright 2, Lauren Peyton 2, R Clayton Bishop 2, Sundeep Basra 2, Fariha Sarwar 2, Grace Winn 2, Karen Chesbrough 2
 
3.Limited sustained remission after nucleos(t)ide analogue withdrawal: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)
 

Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002759. Online ahead of print.

 

Grishma Hirode 1 2 3, Bettina E Hansen 1 4 5, Chien-Hung Chen 6, Tung-Hung Su 7, Grace L H Wong 8, Wai-Kay Seto 9, Arno Furquim d'Almeida 10, Margarita Papatheodoridi 11, Sylvia M Brakenhoff 12, Sabela Lens 13, Hannah S J Choi 1, Rong-Nan Chien 14, Jordan J Feld 1 2 3, Xavier Forns 13, Milan J Sonneveld 12, George V Papatheodoridis 11, Thomas Vanwolleghem 10 15, Man-Fung Yuen 9, Henry L Y Chan 8, Jia-Horng Kao 7, Yao-Chun Hsu 16, Markus Cornberg 17, Wen-Juei Jeng 14, Harry L A Janssen 1 12; RETRACT-B study group
 
4.RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects
 

Microorganisms. 2024 Mar 17;12(3):599. doi: 10.3390/microorganisms12030599.

 

Laura Sneller 1, Christine Lin 1, Angie Price 1, Shyam Kottilil 1, Joel V Chua 1
 
5.Toward a Functional Cure for Hepatitis B
 

Gut Liver. 2024 Mar 27. doi: 10.5009/gnl240023. Online ahead of print.

 

Anna S F Lok 1
 
6.Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses
 

JHEP Rep. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999. eCollection 2024 Apr.

Man-Fung Yuen 1, Scott Fung 2, Xiaoli Ma 3, Tuan T Nguyen 4, Tarek Hassanein 5, Hie-Won Hann 6, Magdy Elkhashab 7, Ronald G Nahass 8, James S Park 9, Ira M Jacobson 10, Walid S Ayoub 11, Steven-Huy Han 12, Edward J Gane 13, Katie Zomorodi 14, Ran Yan 14, Julie Ma 14, Steven J Knox 14, Luisa M Stamm 14, Maurizio Bonacini 15, Frank Weilert 16, Alnoor Ramji 17, Michael Bennett 18, Natarajan Ravendhran 19, Sing Chan 20, Douglas T Dieterich 21, Paul Yien Kwo 22, Eugene R Schiff 23, Ho S Bae 24, Jacob Lalezari 25, Kosh Agarwal 26, Mark S Sulkowski 27
 
7.Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease
 

Aliment Pharmacol Ther. 2024 Mar 22. doi: 10.1111/apt.17967. Online ahead of print.

 

Rohit Loomba 1, Ginger Clark 2, Jeff Teckman 3, Veeral Ajmera 1, Cynthia Behling 1 4, Mark Brantly 5, David Brenner 6, Jeanine D'Armiento 7, Michael W Fried 8, Janani S Iyer 9, Mattias Mandorfer 10, Don C Rockey 11, Monica Tincopa 12, Raj Vuppalanchi 13, Zobair Younossi 14, Aleksander Krag 15, Alice M Turner 16, Pavel Strnad 17
 
8.A systematic review of the effects of hepatitis B and C virus on the progression of liver fluke infection to liver cancer
 

Trop Dis Travel Med Vaccines. 2024 Mar 15;10(1):6.doi: 10.1186/s40794-023-00215-8.

 

Allison O'Rourke 1
 
9.Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study
 

Lancet Glob Health. 2024 Apr;12(4):e563-e571. doi: 10.1016/S2214-109X(23)00603-4.

 

Anna-Maria Hartner 1, Xiang Li 2, Susy Echeverria-Londono 2, Jeremy Roth 2, Kaja Abbas 3, Megan Auzenbergs 4, Margaret J de Villiers 2, Matthew J Ferrari 5, Keith Fraser 2, Han Fu 4, Timothy Hallett 2, Wes Hinsley 2, Mark Jit 6, Andromachi Karachaliou 7, Sean M Moore 8, Shevanthi Nayagam 9, Timos Papadopoulos 10, T Alex Perkins 8, Allison Portnoy 11, Quan Tran Minh 8, Emilia Vynnycky 10, Amy K Winter 12, Holly Burrows 13, Cynthia Chen 14, Hannah E Clapham 15, Aniruddha Deshpande 16, Sarah Hauryski 5, John Huber 17, Kevin Jean 18, Chaelin Kim 19, Jong-Hoon Kim 19, Jemima Koh 14, Benjamin A Lopman 16, Virginia E Pitzer 13, Yvonne Tam 20, Philipp Lambach 21, So Yoon Sim 21, Kim Woodruff 2, Neil M Ferguson 2, Caroline L Trotter 22, Katy A M Gaythorpe 23
 
10.Haemodialysis machine designation for patients with chronic Hepatitis B virus: A practice and attitudes survey of Australian renal healthcare workers
 

Infect Dis Health. 2024 Mar 13:S2468-0451(24)00004-X. doi: 10.1016/j.idh.2024.02.003.Online ahead of print.

 

Sarah Russo 1, Jill Telfer 2, Carla Silva 3, Eliza Daly 3, Sarah Browning 4
 
11.Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology
 

Curr Opin Rheumatol. 2024 Mar 1;36(2):113-119.doi: 10.1097/BOR.0000000000000995. Epub 2023 Dec 20.

Kaia Barth 1, Harsimrat Gill 2, Namrata Singh 3 4
 
12.A cross-sectional survey of viral hepatitis education within pharmacy curricula in the United States
 

Int J Clin Pharm. 2024 Feb 14. doi: 10.1007/s11096-023-01691-w. Online ahead of print.

Michelle T Martin 1 2, Aileen N Pham 3, Jessica S Wagner 3
 
13.Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy
 

Drug Saf. 2024 Feb 14. doi: 10.1007/s40264-024-01399-4. Online ahead of print.

 

Eric B Cohen 1, Arie Regev 2, Anju Garg 3, Adrian M Di Bisceglie 4, James H Lewis 5, John M Vierling 6, Judith Hey-Hadavi 7, Klaudia Steplewski 8, Anna Fettiplace 9, Chunlin L Chen 10, Nonko Pehlivanov 11, Stuart Kendrick 12, Mark I Avigan 13
 
14.The City Clinic Cohort Study: Hepatitis B, HTLV-III/LAV, and CDC AIDS Project 24
 

AIDS Behav. 2024 Jan 18. doi: 10.1007/s10461-023-04187-w. Online ahead of print.

 

William W Darrow 1
 
15.High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment
 

Harm Reduct J. 2024 Jan 29;21(1):25. doi: 10.1186/s12954-024-00942-x.

 

Catherine Campusano 1 2, Rachel Kanner 3, Claire McDonell 4, Meghan Morris 4, Maria Duarte 3, Jennifer C Price 3 5
 
16.Hepatitis B Care Continuum Models-Data to Inform Public Health Action
 

Public Health Rep. 2024 Jan 11:333549231218277.doi: 10.1177/00333549231218277. Online ahead of print.

 

Philip R Spradling 1, Angelica Bocour 2, Danica E Kuncio 3, Kathleen N Ly 1, Aaron M Harris 4, Nicola D Thompson 1
 
17.The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis
 

Hepatology. 2024 Feb 1;79(2):425-437.doi: 10.1097/HEP.0000000000000563. Epub 2023 Aug 23.

 

Xiujuan Chang 1, Caihong Lv 1 2, Bingqiong Wang 3, Jing Wang 4, Zheng Song 1 2, Linjing An 1, Shuyan Chen 3, Yongping Chen 5, Qinghua Shang 6, Zujiang Yu 7, Lin Tan 8, Qin Li 9, Huabao Liu 10, Li Jiang 11, Guangming Xiao 12, Liang Chen 13, Wei Lu 14, Xiaoyu Hu 15, Zheng Dong 1, Yan Chen 1, Yameng Sun 3, Xiaodong Wang 5, Zhiqin Li 7, Da Chen 9, Hong You 3, Jidong Jia 3, Yongping Yang 1 2
 
18.Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in Pregnancy: Updated Guidelines
 

Am J Obstet Gynecol. 2023 Dec 21:S0002-9378(23)02173-7. doi: 10.1016/j.ajog.2023.12.023.Online ahead of print.

Society for Maternal-Fetal Medicine (SMFM); Martina Badell, Malavika Prabhu, Jodie Dionne-Odom, Alan T N Tita, Neil S Silverman; SMFM Publications Committee
 
19.Hepatitis B in Healthcare Personnel: An Update on the Global Landscape
 

Viruses. 2023 Dec 18;15(12):2454. doi: 10.3390/v15122454.

Georgia B Nikolopoulou 1, Ioannis Tzoutzas 2, Athanasios Tsakris 3, Helena C Maltezou 4
 
20.Test All for Hepatitis B Virus: Link to Care and Treatment if Quantitative DNA Positive, Vaccinate if Susceptible
 

Clin Liver Dis. 2023 Nov;27(4):997-1022. doi: 10.1016/j.cld.2023.05.009.Epub 2023 Jul 7.

Katerina Roma 1, Zahra Dossaji 2, Lubaba Haque 2, Tooba Laeeq 2, Robert G Gish 3, Carol Brosgart 4
 
21.Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options
 

United European Gastroenterol J. 2023 Dec 2. doi: 10.1002/ueg2.12494.Online ahead of print.

María Buti 1 2 3, Alexia Gonzalez 4, Mar Riveiro-Barciela 1 2 3, Marc Bourliere 4 5
 
22.Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B
 

Clin Gastroenterol Hepatol. 2023 Nov;21(12):30893096.e1. doi:10.1016/j.cgh.2023.03.024.Epub 2023 Mar 31.

Lesley A Patmore 1, Warshan K Katwaroe 2, Daniel van der Spek 2, Hannah S J Choi 3, Keyur Patel 3, Sylvia Brakenhoff 2, Adriaan J van der Meer 2, Willem P Brouwer 2, Laurens A van Kleef 2, Rob J de Knegt 2, Bettina E Hansen 4, Rob A de Man 2, Jordan J Feld 4, Harry L A Janssen 5, Milan J Sonneveld 2
 
23.The Impact of Living With Chronic Hepatitis B on Quality of Life: Implications for Clinical Management
 

JPatientExp. 2023Nov13:10:23743735231211069. doi:10.1177/23743735231211069.eCollection 2023.

Yasmin Ibrahim 1, Madeleine Umstead 1, Su Wang 2 3, Chari Cohen 1
 
24.Hepatitis B Virus Genotype H: Epidemiological, Molecular, and Clinical Characteristics in Mexico
 

Viruses. 2023 Oct 30;15(11):2186. doi: 10.3390/v15112186.

Arturo Panduro 1 2, Sonia Roman 1 2, Saul Laguna-Meraz 1 2, Alexis Jose-Abrego 1 2
 
25.Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
 

Open Forum Infect Dis. 2023 Nov 14;10(11):ofad551. doi: 10.1093/ofid/ofad551.eCollection 2023 Nov.

Hannes Lindahl 1 2, Anna-Carin Norlin 1 3, Peter Bergman 1 3 4
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.